Welcome to our dedicated page for NeuroBo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals stock.
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company dedicated to developing and commercializing transformative therapies for cardiometabolic diseases. Headquartered in Boston, Massachusetts, and established in 2017, NeuroBo is at the forefront of innovative solutions aimed at conditions like obesity, metabolic dysfunction-associated steatohepatitis (MASH), and Type 2 Diabetes Mellitus (T2DM).
The company's robust product pipeline includes two primary programs:
- DA-1241: This novel G-Protein-Coupled Receptor 119 (GPR119) agonist aims to treat MASH and T2DM. In preclinical studies, DA-1241 has shown promising results in reducing hepatic steatosis, inflammation, liver fibrosis, and improving glucose control. The Phase 2a clinical trial is currently evaluating its efficacy and safety, with an expected data readout in the second half of 2024.
- DA-1726: A dual oxyntomodulin (OXM) analog functioning as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, designed to address obesity. Preclinical evidence suggests that DA-1726 offers superior weight loss and a better tolerability profile compared to existing GLP-1 agonists. The Phase 1 clinical trial is underway with an anticipated data readout in the first half of 2025.
In addition to its primary programs, NeuroBo continues to advance its legacy therapeutics, including ANA001 for viral diseases, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia. The company's commitment to leveraging advanced biotechnology aims to meet significant unmet medical needs, providing patients with novel, effective treatments.
Recent achievements include FDA clearance for the IND application of DA-1726 and the initiation of Phase 1 clinical trials. NeuroBo also secured Institutional Review Board (IRB) approval to further expedite their research and development processes.
For more comprehensive information, please visit NeuroBo Pharmaceuticals' official website.
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has submitted an IND application to the FDA for a Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for the treatment of obesity. The company aims to address the significant obesity market with a potential new treatment that has shown promising preclinical evidence of weight loss in animal models. The first dose is expected to be administered in the first half of 2024, with data readout anticipated in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) announces a 1-for-8 reverse stock split, reducing outstanding shares from 38.8 million to approximately 4.85 million. The split will be effective on December 21, 2023, to comply with Nasdaq's listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company (Nasdaq: NRBO), announced that its executives will present updates on its cardiometabolic assets, DA-1241 and DA-1726, at two investor conferences in December. The company's focus on transformation of cardiometabolic diseases will be highlighted at the Investor Summit Virtual Conference on December 7 and the Life Science Virtual Investor Forum on December 14. Interested investors can register through the Life Science Virtual Investor Forum platform. The live webcast and archived replay of both presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
News
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for Q3 2023, with cash and cash equivalents of $25.8 million expected to fund operations through Q4 2024. The company provided updates on the clinical development of their cardiometabolic assets, including the Phase 2a clinical trial of DA-1241 for NASH and preclinical testing results of DA-1726 for obesity. They also highlighted the appointment of James P. Tursi, M.D. to the Board of Directors and the out-licensing agreement with MTHERA for NB-01.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
-
News
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. has appointed James P. Tursi, a pharmaceutical industry veteran, to its Board of Directors. Dr. Tursi brings nearly 20 years of experience in the pharmaceutical industry and over 30 years of medical experience. He will provide valuable expertise as the company advances the clinical development of its cardiometabolic assets. NeuroBo is currently developing DA-1241, a novel GPR119 agonist, for the treatment of NASH, and DA-1726, a novel GLP1R and GCGR dual agonist, for obesity. Dr. Tursi's appointment is expected to drive shareholder value and maximize the potential of NeuroBo's next-generation pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals to present at H.C. Wainwright 7th Annual NASH Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
Rhea-AI Summary
NeuroBo Pharmaceuticals begins Phase 2a trial of DA-1241 for NASH treatment, with potential interim analysis in H1 2024 and full data readout in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.94%
Tags
-
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) appoints Hyung Heon Kim as CEO and President, leveraging his expertise in advancing DA-1241 and DA-1726, potential therapies for NASH, obesity, and type 2 diabetes. Kim's deep familiarity with the assets and strong working relationship with partner Dong-A positions NeuroBo for clinical development and market leadership in cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
-
News
Rhea-AI Summary
NeuroBo Pharmaceuticals announces progress in cardiometabolic assets, including FDA approval for DA-1241 and positive preclinical data on DA-1726. Signed term sheet with MTHERA for out-licensing of NB-01. Cash and Cash Equivalents of $28.7 million expected to fund operations into 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.21%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
FAQ
What is the current stock price of NeuroBo Pharmaceuticals (NRBO)?
The current stock price of NeuroBo Pharmaceuticals (NRBO) is $2.35 as of November 21, 2024.
What is the market cap of NeuroBo Pharmaceuticals (NRBO)?
The market cap of NeuroBo Pharmaceuticals (NRBO) is approximately 20.2M.
What is NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies for cardiometabolic diseases.
What are NeuroBo's primary programs?
NeuroBo's primary programs include DA-1241 for the treatment of MASH and T2DM, and DA-1726 for the treatment of obesity.
What is DA-1241?
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist designed to treat MASH and T2DM. It has shown promising preclinical results in reducing liver inflammation and improving glucose control.
What is DA-1726?
DA-1726 is a dual oxyntomodulin (OXM) analog that functions as a GLP1R and GCGR agonist for treating obesity. It has demonstrated superior weight loss in preclinical models.
Where is NeuroBo Pharmaceuticals headquartered?
NeuroBo Pharmaceuticals is headquartered in Boston, Massachusetts.
When was NeuroBo Pharmaceuticals founded?
NeuroBo Pharmaceuticals was founded in 2017.
What recent initiatives has NeuroBo announced?
NeuroBo recently announced FDA clearance for the IND application of DA-1726 and achieved IRB approval to proceed with its Phase 1 clinical trials.
What are NeuroBo's legacy therapeutics?
NeuroBo's legacy therapeutics include ANA001 for viral diseases, NB-01 for painful diabetic neuropathy, NB-02 for neurodegenerative diseases, and Gemcabene for dyslipidemia.
How can I learn more about NeuroBo Pharmaceuticals?
For more information, visit NeuroBo Pharmaceuticals' official website at www.neurobopharma.com.
What is the significance of DA-1726?
DA-1726 could be a groundbreaking treatment for obesity, offering better weight loss and tolerability compared to existing GLP-1 agonists.
NeuroBo Pharmaceuticals, Inc.
Nasdaq:NRBO
NRBO Rankings
NRBO Stock Data
20.25M
3.00M
65.24%
12.71%
0.23%
Biotechnology
Pharmaceutical Preparations
United States of America
CAMBRIDGE